- Home
- FATE
as 11-15-2024 4:00pm EST
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 406.5M | IPO Year: | 2013 |
| Target Price: | $6.89 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.64 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.96 - $8.83 | Next Earning Date: | 11-12-2024 |
| Revenue: | $13,447,000 | Revenue Growth: | -87.34% |
| Revenue Growth (this year): | -81.89% | Revenue Growth (next year): | -67.76% |
Latest Fate Therapeutics Inc. News
FATE Breaking Stock News: Dive into FATE Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
Fate Therapeutics, Inc. (NASDAQ:FATE) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Simply Wall St.
3 days ago
Fate Therapeutics Third Quarter 2024 Earnings: Beats Expectations
Zacks
4 days ago
FATE Q3 Earnings Beat on Higher Revenues, Pipeline in Focus
Zacks
5 days ago
Fate Therapeutics (FATE) Reports Q3 Loss, Tops Revenue Estimates
Associated Press Finance
5 days ago
Fate Therapeutics: Q3 Earnings Snapshot
GlobeNewswire
5 days ago
Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates
GlobeNewswire
8 days ago
Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting
MT Newswires
9 days ago
Fate Therapeutics Reports Positive Preclinical Data for Cancer Treatment Candidate
Compare FATE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FATE Fate Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.